Category Archives: Business and Investments

Latest From Business and Investments

Just how big is $11 Billion? GILD Acquires VRUS

Seeing the markets open down 2% or more on a Monday morning feels like “business as usual” on Wall Street these days. What is not, is seeing the Nasdaq Biotech Index (NBI) shoot up 4.5% on the same day the markets are cratering. It is very rare these days to find any sector not correlating with the volatile downturns set off by debt laden countries around the globe. So what is behind the inverse correlation Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , ,

Opportunity or Apocalypse? Prophecies for 2012

BIF Closing Plenary

On day two of the BIO Investor Forum in San Francisco, Calif., attendees were eager to participate in the Closing Plenary. Historically, this session draws the biggest crowd of the conference and this year was no exception. Speaking to a packed audience, with standing room only, the panelists engaged in a lively discussion about the state of the industry and what is in the cards for 2012. Both Bryan Roberts, PhD, Partner, Venrock and Matthew Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , ,

Public Exits and Virtual Biotechs – Dreams or Reality?

Here at the 10th Annual BIO Investor Forum, investors and CEOs are debating “all the options” for private companies. The first panel of the conference explored the backdoor entrance into public markets as chilly winds continue to blow through the latest IPO window. For the lunch plenary, panelists examined the option to go virtual and make capital efficiency a reality. Reverse Mergers It is no secret that the IPO market for biotechs has been tough. Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Reverse Mergers: A Company is Ready to Go Public, or it’s Not

The latest IPO window has stalled. There have been five IPO withdrawals since June and around 30 since 2005. Global macro events are threatening to completely shut it. Reverse mergers have become an increasingly popular option with eight transactions in the last year. Unfortunately, 47 percent of reverse mergers have decreased in value post-close since 2008. At the 2011 BIO Investor Forum, a panel of experts examined the current financing environment and what private executive Read More >

Business of Biotech  |  2 Comments  |  Email This Post
Tags: , , , ,

BIO Investor Forum Company Snapshot: Protagonist Therapeutics

Protagonist

In our final Investor Forum Company Snapshot, we’ve profiled one of the Discovery Companies who will be presenting at the event. Protagonist Therapeutics shares their take on funding challenges and upcoming priorities, plus interesting facts about their company. Don’t miss their presentation first thing Tuesday morning! Company Snapshot What are the short-term and long-term priorities for your company? Protagonist is a peptide therapeutics based technology platform company. Short term priority:  Secure a second collaboration and Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,